We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

131 hedge funds and large institutions have $829M invested in Intra-Cellular Therapies Inc. in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 47 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more capital invested

Capital invested by funds: $553M → $829M (+$276M)

47% more call options, than puts

Call options by funds: $30.8M | Put options by funds: $21M

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

0% more funds holding

Funds holding: 131 → 131 (0)

13% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 47

Holders
131
Holders Change
–
Holders Change %
0%
% of All Funds
3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
41
Reduced
47
Closed
19
Calls
$30.8M
Puts
$21M
Net Calls
+$9.81M
Net Calls Change
+$5.83M

Top Buyers

1
PC
PointState Capital
New York
+$36.4M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$21.8M
3
Citadel Advisors
Citadel Advisors
Florida
+$18.9M
4
DFO
Duquesne Family Office
New York
+$5.79M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$5.69M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$17.2M
2
BBA
Baker Bros. Advisors
New York
-$8.82M
3
SC
Samlyn Capital
New York
-$6.83M
4
RPAM
Rhenman & Partners Asset Management
Sweden
-$5.69M
5
BlackRock
BlackRock
New York
-$4.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
SWM
76
SeaCrest Wealth Management
New York
$615K +$4.32K +222 +0.8%
EIM
77
Essex Investment Management
Massachusetts
$578K +$535K +27,443 New
AIG
78
American International Group
New York
$571K -$28.4K -1,460 -5%
QIM
79
Quantitative Investment Management
Virginia
$547K +$506K +26,000 New
Wells Fargo
80
Wells Fargo
California
$534K +$59.7K +3,065 +14%
State of Wisconsin Investment Board
81
State of Wisconsin Investment Board
Wisconsin
$505K – – –
EMG
82
ETF Managers Group
New Jersey
$460K +$463K +23,765 New
AWCI
83
Alpine Woods Capital Investors
New York
$442K -$1.95K -100 -0.5%
MIM
84
MetLife Investment Management
New Jersey
$413K +$50.9K +2,613 +15%
PAM
85
Premier Asset Management
Illinois
$402K +$44.1K +2,262 +13%
PCM
86
Prelude Capital Management
New York
$392K +$340K +17,470 +1,487%
VF
87
Virtu Financial
New York
$390K +$361K +18,538 New
VOYA Investment Management
88
VOYA Investment Management
Georgia
$380K – – –
TI
89
Trexquant Investment
Connecticut
$374K -$378K -19,423 -52%
Citigroup
90
Citigroup
New York
$371K +$26.9K +1,380 +9%
TAM
91
Tocqueville Asset Management
New York
$370K -$127K -6,500 -27%
DADC
92
D.A. Davidson & Co
Montana
$363K +$336K +17,257 New
KeyBank National Association
93
KeyBank National Association
Ohio
$360K -$93.3K -4,791 -22%
State Board of Administration of Florida Retirement System
94
State Board of Administration of Florida Retirement System
Florida
$359K +$15.5K +797 +5%
Legal & General Group
95
Legal & General Group
United Kingdom
$327K -$59.6K -3,058 -16%
FMT
96
First Mercantile Trust
Tennessee
$316K -$11.4K -583 -4%
UBS AM
97
UBS AM
Illinois
$309K – – –
Stifel Financial
98
Stifel Financial
Missouri
$304K – – –
MLICM
99
Metropolitan Life Insurance Company (MetLife)
New York
$295K +$14.9K +766 +6%
CG
100
Cutler Group
California
$275K +$82.6K +4,238 +48%
2 3
4
5 6

ITCI Hedge Fund Activity: Q1 2018 in Review

131 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2018, worth a combined $829M — up 50% from $553M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ITCI positions and 19 closed out — a net gain of 1 holder — while 41 added to existing stakes and 47 trimmed.

The largest buyer was PointState Capital, opening a new position worth an estimated $36.4M. The largest seller was Millennium Management, cutting an estimated $17.2M.

  • 131 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $829M of Intra-Cellular Therapies Inc. stock for Q1 2018, up 50% quarter-over-quarter.
  • 20 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2018 and 19 closed out, a net change of +1 holder.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2018 was PointState Capital, an estimated $36.4M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q1 2018 was Millennium Management, an estimated $17.2M sold.

Based on aggregated 13F filings for Q1 2018.